Concepedia

Publication | Closed Access

A Dose Escalation Study of Gemcitabine plus Pemetrexed Administered Biweekly in Patients with Solid Tumors

DOI

10

Citations

22

References

2006

Year

A. Kalykaki, L. Vamvakas, Sofia Agelaki, Kostas Kalbakis, N. Vardakis, G. Sfakiotaki, M. Ignatiadis, Zacharenia Saridaki, Athanasios Karampeazis, D. Mavroudis,
Oncology

Abstract

The biweekly administration of gemcitabine plus pemetrexed at the recommended MTDs is safe, well tolerated and demonstrates antitumor activity which merits further evaluation in phase II studies.

References

YearCitations

Page 1